From Wikipedia, the free encyclopedia
Jump to: navigation,
search
Cefprozil
 |
| Systematic (IUPAC) name |
| 7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Identifiers |
| CAS number |
92665-29-7 |
| ATC code |
J01DC10 |
| PubChem |
CID 5281006 |
| DrugBank |
APRD00461 |
| ChemSpider |
4941253 |
| Chemical data |
| Formula |
C18H19N3O5S |
| Mol. mass |
389.427 g/mol |
| SMILES |
eMolecules & PubChem |
| Pharmacokinetic data |
| Bioavailability |
95% |
| Protein binding |
36% |
| Half-life |
1.3 hours |
| Therapeutic considerations |
| Pregnancy cat. |
Category-B |
| Legal status |
|
| Routes |
ORAL |
 Y(what is this?) (verify)
|
Cefprozil, sometimes spelled cefproxil and sold under the brand name Cefzil, is a second-generation cephalosporin type antibiotic. In Europe, it is sold by the name Procef and Cronocef. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. It comes as a tablet and as a liquid suspension.
Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006)1 has shown no increased risk for cross-allergy for cefprozil and several other 2nd generation or later cephalosporins.
References
- ^ http://www.jfponline.com/pdf%2F5502%2F5502JFP_AppliedEvidence1.pdf
External links
- Information about Cefprozil
|
Antibacterials: cell envelope antibiotics (J01C-J01D) |
|
Internal to membrane/
(inhibit peptidoglycan subunit
synthesis and transport) |
NAM synthesis inhibition (Fosfomycin) · DADAL/AR inhibitors (Cycloserine) · bactoprenol inhibitors (Bacitracin)
|
|
Glycopeptide/
(inhibit PG chain elongation) |
Vancomycin# (Oritavancin, Telavancin) · Teicoplanin (Dalbavancin) · Ramoplanin
|
|
β-lactams/
(inhibit cross-links
with PBP) |
|
Penicillins/
(penams)
|
|
Extended sp.
|
aminopenicillins: Amoxicillin# · Ampicillin# (Pivampicillin, Hetacillin, Bacampicillin, Metampicillin, Talampicillin) · Epicillin
carboxypenicillins: Carbenicillin (Carindacillin) · Ticarcillin · Temocillin
ureidopenicillins: Azlocillin · Piperacillin · Mezlocillin
other: Mecillinam (Pivmecillinam) · Sulbenicillin
|
|
|
Narrow sp.
|
|
β-lactamase sensitive
|
Benzylpenicillin (G)#: Clometocillin · Benzathine benzylpenicillin# · Procaine benzylpenicillin# · Azidocillin · Penamecillin
Phenoxymethylpenicillin (V) #: Propicillin · Benzathine phenoxymethylpenicillin · Pheneticillin
|
|
|
β-lactamase resistant
|
Cloxacillin# (Dicloxacillin, Flucloxacillin) · Oxacillin · Meticillin · Nafcillin
|
|
|
|
|
Penems
|
Faropenem
|
|
|
Carbapenems
|
Biapenem · Doripenem · Ertapenem · Imipenem · Meropenem · Panipenem
|
|
|
Cephalosporins/
(cephems)
|
|
1st (PEcK)
|
Cefazolin# · Cefacetrile · Cefadroxil · Cefalexin · Cefaloglycin · Cefalonium · Cefaloridine · Cefalotin · Cefapirin · Cefatrizine · Cefazedone · Cefazaflur · Cefradine · Cefroxadine · Ceftezole
|
|
|
2nd (HEN)
|
Cefaclor · Cefamandole · Cefminox · Cefonicid · Ceforanide · Cefotiam · Cefprozil · Cefbuperazone · Cefuroxime · Cefuzonam · cephamycin (Cefoxitin, Cefotetan, Cefmetazole) · carbacephem (Loracarbef)
|
|
|
3rd
|
Cefixime# · Ceftazidime# · Ceftriaxone# · Cefcapene · Cefdaloxime · Cefdinir · Cefditoren · Cefetamet · Cefmenoxime · Cefodizime · Cefoperazone · Cefotaxime · Cefpimizole · Cefpiramide · Cefpodoxime · Cefsulodin · Cefteram · Ceftibuten · Ceftiolene · Ceftizoxime · oxacephem (Flomoxef, Latamoxef ‡)
|
|
|
4th
|
Cefepime · Cefozopran · Cefpirome · Cefquinome
|
|
|
5th
|
Ceftobiprole · Ceftaroline
|
|
|
Veterinary
|
Ceftiofur · Cefquinome · Cefovecin
|
|
|
|
Monobactams
|
Aztreonam · Tigemonam · Carumonam
|
|
|
β-lactamase inhibitors
|
penam (Sulbactam, Tazobactam) · clavam (Clavulanic acid)
|
|
|
Combinations
|
Co-amoxiclav (Amoxicillin/clavulanic acid)# · Imipenem/cilastatin# · Ampicillin/sulbactam (Sultamicillin) · Piperacillin/tazobactam
|
|
|
| Other |
polymyxins/detergent (Colistin, Polymyxin B) · depolarizing (Daptomycin) · hydrolyze NAM-NAG (Lysozyme)
|
|
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III
|
|
|
gr+f/gr+a(t)/gr-p(c)/gr-o
|
|
|
|
|
